Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Perindopril/indapamide 2/0.625 mg/day - A review of its place in the management of hypertension
Autore:
Matheson, AJ; Cheer, SM; Goa, KL;
Indirizzi:
Adis Int Ltd, Auckland 10, New Zealand Adis Int Ltd Auckland New Zealand10 s Int Ltd, Auckland 10, New Zealand
Titolo Testata:
DRUGS
fascicolo: 8, volume: 61, anno: 2001,
pagine: 1211 - 1229
SICI:
0012-6667(2001)61:8<1211:P2M-AR>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DOSE COMBINATIONS; PHARMACOLOGICAL PROPERTIES; INDAPAMIDE; THERAPY; EFFICACY; RATS; RATIONALE; INHIBITOR;
Keywords:
perindopril; indapamide; combination therapy; ACE inhibitors; diuretics; mild hypertension; moderate hypertension; pharmacodynamics; pharmacokinetics; therapeutic use;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Matheson, AJ Adis Int Ltd, 41 Centorian Dr,Private Bag 65901,Mairangi Bay,Auckland 10,New Zealand Adis Int Ltd 41 Centorian Dr,Private Bag 65901,Mairangi Bay Auckland New Zealand 10
Citazione:
A.J. Matheson et al., "Perindopril/indapamide 2/0.625 mg/day - A review of its place in the management of hypertension", DRUGS, 61(8), 2001, pp. 1211-1229

Abstract

The Axed low-dose combination of the ACE inhibitor perindopril and the non-thiazide diuretic indapamide has been evaluated in the management of patients with mild to moderate hypertension. Combination therapy aims to improveoverall therapeutic efficacy while minimising adverse effects. In well-designed multicentre clinical trials. perindopril/indapamide at doses ranging from 2/0.625 to 8/2.5 mg/day was significantly more effective than placebo in achieving adequate blood pressure (BP) control, A similar reduction in supine BP was observed when combined perindopril/indapamide 2/0.625 mg/day was compared with losartan 50 mg/day or atenolol 50 mg/day, Similar reductions in 24-hour ambulatory BP were also seen with perindopril/indapamide 2/0.625 mg/day and irbesartan 150 mg/day, However, response and normalisation rates were significantly higher with combination therapy than with losartan or irbesartan monotherapy. Combined perindopril/indapamide 2/0.625 mg/day therapy effectively reducedBP in elderly patients aged 65 to 85 years to a significantly greater extent than either atenolol 50 mg/day or placebo, Supine BP was also normalisedin approximately two-thirds of patients in a small noncomparative trial inpatients with hypertension and renal impairment. Low-dose perindopril/indapamide 2/0.625 mg/day was well tolerated in clinical trials: the most common adverse events were headache and cough, Hypokalaemia, associated with the use of diuretics, occurred with a higher incidence with combined perindopril/indapamide 2/0.625 mg/day therapy than with either atenolol 50 mg/day or placebo. Perindopril/indapamide 2/0.625 mg/day has shown efficacy in well designed comparative trials with atenolol. losartan and irbesartan including elderlypatients and patients with renal impairment, Studies comparing this dosageof perindopril/indapamide with other combination therapies would be beneficial in allowing the place of perindopril/indapamide to be more accurately determined, The fixed-low dose combination of perindopril/indapamide provides a promising and well tolerated treatment option in the management of patients with mild to moderate hypertension.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 09:45:14